Comments
Drug maker Lupin on Monday said it has received approval from the US health regulator to market Lurasidone Hydrochloride tablets, used in the treatment of schizophrenia, in the American market.
The company said it has received approval from the US Food and Drug Administration (FDA) to market its product, which is a generic version of Sunovion Pharmaceuticals Inc’s Latuda tablets, in strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, Lupin said in a regulatory filing.
The drug is indicated for conditions like schizophrenia and bipolar depression.
As per IQVIA MAT September 2018 data, Latuda tablets had sales of around USD 3,217.3 million in the US market.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.